Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Sensodyne-maker Haleon posts tepid sales as demand for some products cool off

Published 05/01/2024, 03:01 AM
Updated 05/01/2024, 04:15 AM
© Reuters. FILE PHOTO: FILE PHOTO: Sensodyne toothpaste and Panadol tablets are seen in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
HLN
-

(Reuters) -Consumer healthcare company Haleon reported first-quarter revenue slightly below market estimates on Wednesday, as volumes declined due to retailer destocking in U.S. and cooling demand for some of its medicines after a surge last year.

The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year.

Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth.

Revenues stood at 2.92 billion pounds ($3.64 billion) for the quarter ended March 31, slightly missing expectations of 2.93 billion pounds, according to a company-compiled consensus.

On a reported basis, revenue was down 2.2% on last year.

"The miss in volumes more than offsets a (played down) margin beat, outlook no change. We could expect the stock to be an under performer this AM," Jefferies analysts said.

Shares in the FTSE 100 group fell 1.8% to 333.30 pence, to become one of the top losers on the blue-chip index. The stock has risen about 5% this year as of Tuesday's close.

Haleon, whose name is inspired by the merging 'Hale', which is an old English word that means 'in good health', and Leon which is associated with the word 'strength'.

It comprises assets from GSK and Pfizer (NYSE:PFE) and sells non-prescription drugs, vitamins and oral care products. It was spun-off from GSK in 2022.

Demand for its oral health products and multivitamins held steady during the reported quarter, and the company re-affirmed its full-year outlook outlined in February.

Adjusted operating profit grew 2.3% to 707 million pounds in the first quarter.

© Reuters. FILE PHOTO: FILE PHOTO: Sensodyne toothpaste and Panadol tablets are seen in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

On Tuesday, the firm disclosed plans to shut its UK production site which makes Sensodyne toothpastes by 2026, saying it was not longer viable to manufacture its products there.

($1 = 0.8021 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.